AngioDynamics has set its fiscal 2027 net sales guidance at $336 million to $341 million, with adjusted EBITDA expected between $13 million and $16 million. Within that, Med Tech net sales are projected to grow 12% to 15% year-over-year, while Med Device sales are seen roughly flat. Gross margin is forecast at 54% to 55%, and the company anticipates an adjusted loss per share of $0.29 to $0.24. The outlook follows a fourth quarter in which revenue rose 8% to $86.6 million, led by a 64.5% surge in NanoKnife revenue to $11.8 million, while Mechanical Thrombectomy revenue dipped 1.1% to $11.1 million amid a commercial reset. Management also noted that a CEO succession is expected during the first half of fiscal 2027.
AngioDynamics IncCompany issued fiscal 2027 guidance with Med Tech net sales growth of 12-15% and improved gross margin of 54-55%.